Changzhou No.2 People's Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.czey.com

Clinical Trials

Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus

Completed

Conditions: Dislocated Lens
Pars Plana Vitrectomy
Phacoemulsification
Needle

First Posted Date: 2024-11-28

Last Posted Date: 2024-11-28

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 9

Registration Number: NCT06709378

Locations: 🇨🇳
the Second People's Hospital of Changzhou, Changzhou, Jiangsu, China

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Biological: γδ T-PD-1 Ab cells

First Posted Date: 2024-05-08

Last Posted Date: 2024-08-22

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 9

Registration Number: NCT06404281

Locations: 🇨🇳
Changzhou No.2, Changzhou, China

FMT+SOX+Sintilimab as First-line Treatment for Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Combination Product: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 198

Registration Number: NCT06405113

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Combination Product: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy

First Posted Date: 2024-05-07

Last Posted Date: 2024-12-20

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 62

Registration Number: NCT06403111

Locations: 🇨🇳
Changzhou No.2 Poeple's Hospital, Changzhou, China

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Early Phase 1

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: NKG2D Chimeric Antigen Receptor NK Cell Injection

First Posted Date: 2024-04-23

Last Posted Date: 2024-04-23

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 9

Registration Number: NCT06379451

Locations: 🇨🇳
Changzhou Second People's Hospital, Changzhou, Jiangsu, China

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Early Phase 1

Not yet recruiting

Conditions: Thrombocytopenia Alloimmune

Interventions: Drug: anti-CD19 CAR NK cells (KN5501)

First Posted Date: 2024-03-29

Last Posted Date: 2024-07-22

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 9

Registration Number: NCT06337474

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Phase 2

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Apatinib
Drug: S-1

First Posted Date: 2018-09-07

Last Posted Date: 2018-09-19

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 30

Registration Number: NCT03662035

Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer

Phase 2

Conditions: Esophageal Cancer

Interventions: Other: chemoradiotherapy
Other: without thalidomide
Drug: thalidomide

First Posted Date: 2012-03-13

Last Posted Date: 2016-02-17

Lead Sponsor: Changzhou No.2 People's Hospital

Target Recruit Count: 180

Registration Number: NCT01551641

Locations: 🇨🇳
Changzhou No.2 People's Hospital, Changzhou City, Jiangsu, China

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy